A Phase I Study Of The Vascular Disrupting Combretastatin, OXi4503, In Patients With Relapsed and Refractory Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS)

被引：10
|
作者：
Turner, Daniel
Gonzalez, Andres
Pettiford, Leslie
Meacham, Amy
Wise, Elizabeth
Bosse, Raphael C.
Chaplin, Dai
Hsu, Jack W.
Brown, Randy A.
Hiemenz, John W.
Norkin, Maxim
Wingard, John R.
Cogle, Christopher R.
机构：
来源：
BLOOD | 2013年 / 122卷 / 21期
关键词：
D O I：
10.1182/blood.V122.21.1463.1463
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1463
引用
收藏
页数：2
相关论文
共 50 条
  • [1] A Phase I Study of the Vascular Disrupting Combretastatin, OXi4503, in Patients with Relapsed and Refractory Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS)
    Cogle, Christopher R.
    Gonzalez, Andres
    Pettiford, Leslie
    Meacham, Amy
    Wise, Elizabeth
    Norkin, Maxim
    Chaplin, David
    Balkissoon, Jai
    Hsu, Jack W.
    Brown, Randy A.
    Hiemenz, John W.
    Wingard, John R.
    [J]. BLOOD, 2012, 120 (21)
  • [2] The Vascular Disrupting Agent OXi4503 in Relapsed and Refractory AML and MDS
    Stockton, Shannon Somer
    Pettiford, Leslie
    Cline, Christina
    Chaplin, David
    Hsu, Jack W.
    Wingard, John R.
    Cogle, Christopher R.
    [J]. BLOOD, 2015, 126 (23)
  • [3] Safety, feasibility and preliminary efficacy of single agent combretastatin A1 diphosphate (OXi4503) in patients with relapsed or refractory acute myeloid leukemia or myelodysplastic syndromes
    Cogle, Christopher R.
    Collins, Bradley
    Turner, Daniel
    Pettiford, Leslie C.
    Bosse, Raphael
    Hawkins, Kimberly E.
    Beachamp, Zackary
    Wise, Elizabeth
    Cline, Christina
    May, William S.
    Moreb, Jan S.
    Hsu, Jack
    Hiemenz, John
    Brown, Randall
    Norkin, Maxim
    Wingard, John R.
    Uckun, Fatih
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 2020, 189 (05) : E211 - E213
  • [4] Phase I evaluation of vascular disrupting agent OXi4503
    Patterson, D. M.
    Charnley, N.
    Saleem, A.
    Stratford, M.
    Dickinson, C.
    Asselin, M.
    Ross, P.
    Walicke, P.
    Price, P.
    Rustin, G. J.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [5] Phase I evaluation of OXi4503, a vascular disrupting agent, in patients with advanced solid tumours
    Patterson, D. M.
    Ross, P.
    Koetz, B.
    Saleem, A.
    Stratford, M.
    Stirling, J.
    Padhani, A.
    Asselin, M.
    Price, P.
    Rustin, G. J.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [6] A Phase 1B Clinical Study of Combretastatin A1 Diphosphate (OXi4503) and Cytarabine (ARA-C) in Combination (OXA) for Patients with Relapsed or Refractory Acute Myeloid Leukemia
    Uckun, Fatih M.
    Cogle, Christopher R.
    Lin, Tara L.
    Qazi, Sanjive
    Trieu, Vuong N.
    Schiller, Gary
    Watts, Justin M.
    [J]. CANCERS, 2020, 12 (01)
  • [7] A Phase 1b (OX1222) Dose-Finding Study of OXi4503 Combined with Cytarabine in Patients with Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome
    Watts, Justin M.
    Swords, Ronan T.
    Cogle, Christopher R.
    Lin, Tara L.
    [J]. BLOOD, 2016, 128 (22)
  • [8] Phase II study of Mylotarg plus Troxatyl in patients with refractory acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS).
    Giles, FJ
    Garcia-Manero, G
    O'Brien, S
    Estey, E
    Kantarjian, H
    [J]. BLOOD, 2001, 98 (11) : 212B - 212B
  • [9] A phase I/II study of topotecan, mitoxantrone and etoposide in relapsed/refractory acute myeloid leukemia (AML), myeloid blast crisis and high risk myelodysplastic syndromes (MDS).
    Nand, S
    Stiff, P
    Beltran, O
    Godwin, J
    [J]. BLOOD, 1999, 94 (10) : 234B - 234B
  • [10] Evaluation of Rigosertib in Patients with a Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML) Relapsed or Refractory to Hypomethylating Agents: A Phase I/II Study
    Navada, Shyamala C.
    Odchimar-Reissig, Rosalie
    Reddy, E. Premkumar
    Holland, James F.
    Wilhelm, Francois
    Silverman, Lewis R.
    [J]. BLOOD, 2012, 120 (21)
12345